Petrelintide Research: What 4 Studies Show (2026) | RetatrutideCompare

Petrelintide — 4 studies indexed on PubMed. Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA. Half-life: ~7 days. FDA status: Investigational (Phase 2).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Petrelintide?

There are approximately 4 studies indexed on PubMed that mention Petrelintide (ZP-8396), based on a search last updated 2026-06-18.

Is Petrelintide FDA-approved?

FDA status: Investigational (Phase 2).

How does Petrelintide work?

Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.

Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.

Reference facts

Also known as
ZP-8396
Category
GLP-1 & Metabolic
Mechanism of action
Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.
Targets
AMY1R, AMY3R, Calcitonin receptor
Indications under research or approved
Obesity
Regulatory status (reference entry)
Investigational (Phase 2)
Half-life
~7 days
Sequence notes
Long-acting amylin analog from Zealand Pharma with proprietary fatty-acid linker.
Originator / sponsor
Zealand Pharma
First reported
2023

Primary References

Explore research articles about Petrelintide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.